Jung Won Shin
Jung Won is a reporter based in Seoul covering South Korea, most recently working for PharmAsia News. Her work covers corporate activities in the South Korean pharma/biotech sector as well as government policy and regulatory news. In her role, Jung Won focuses on R&D strategies, clinical development, licensing deals and other major corporate deals and activities in the country's pharma/biotech sector as well as major government measures or regulatory activities in the sector.
Prior to joining Informa, Jung Won worked for Dow Jones Newswires in Seoul, covering stories in various industries and government. Outside of work, she likes to travel and spend time with her family and friends.
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From Jung Won Shin
Celltrion has received approval to begin clinical trials of its biosimilar infliximab in China and also filed IND applications for other biosimilar products with the CFDA, accelerating plans to enter the world’s second biggest pharma market as it propels efforts for global leadership in the biosimilar space.
Amid an escalating tussle with the health ministry over the level of South Korean drug prices, foreign pharma firms operating in the country are now proposing the launch of a new joint study on the issue with the incoming government.
South Korean bioventure OliPass tells Scrip how it intends to grab a leading position in the global antisense oligonucleotide drug sector using in-house developed technology that it says can both sharply lower prices and increase safety in the field, where it is initially focusing on novel pain therapies.
New South Korean President Moon Jae-in appears likely to continue to nurture the pharma and biotech industries by generally favorable policies such as improving the domestic drug pricing system to aid the global market entry of locally-originated novel drugs, and looks set to consider industry proposals for a new government R&D ‘control tower’.
A licensing deal between the two cancer-focused biotechs falls apart amidst investor unrest at Immunomedics. Novartis opts to license Conatus' Phase II NASH candidate and picks up a CAR-T candidate from Celyad, while Shire adds to its dry eye franchise in deal with Parion.
Samsung Bioepis, which has received its first US biosimilar approval, is now set to compete with compatriot rival firm Celltrion in the US infliximab biosimilar sector, where discounting is being seen as a key factor in the uptake of these products.